This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Multiple sclerosis (MS) features a substantial white matter (WM) pathology in the brain, which manifests as focal lesions and reduced volume (or atrophy) compared with healthy controls. In addition, extensive gray matter (GM) atrophy is strongly prevalent in MS and highly clinically relevant but can be difficult to measure, especially in a clinical setting.1 Recent work has shown clear patterns of GM atrophy in patients with MS2 that are focused on brain network hubs, i.e., regions that are strongly connected with the rest of the brain. These areas are important for cognitive decline and disability progression and include the thalamus3 and other regions belonging to the default-mode2,4 and motor networks.2 There has been a recent surge of interest in the thalamus, with some hope that thalamic atrophy and its associated dysfunction may be a treatment target of especially high potential3 because thalamic atrophy can be measured relatively easily. The value of including thalamic atrophy as a trial endpoint in clinical trials with disease-modifying treatment in MS is emerging.5
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 686
- © 2018 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.